Aerie Pharma (AERI) PT Raised to $40 at Cantor Fitzgerald

Cantor Fitzgerald analyst Caroline Corner reiterated a Buy rating and boosted her price target on Aerie Pharma (NASDAQ: AERI) to $40.00 (from $30.00) after the company announced positive results from the Rhopressa Phase III Rocket 2 trial.

Corner commented, "We are pleased to see this development and, as we expected, the company said it will file for a New Drug Application (NDA) in mid-2016, which we think puts the company on track for product launch, if approved, in mid-2017."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $18.00 yesterday.

You May Also Be Interested In

• Upexi inc. (UPXI) Reiterated at Overweight by Cantor Fitzgerald Post Price Shortfall
• HubSpot Inc (HUBS) PT Raised to $290 at UBS, Stock Expected to Be Execution-Driven Near-Term
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2